First Patient In: Weekly Clinical Trials Briefing
We tracked seven first-patient-in milestones between 6 and 13 November. The US led with four, including two eye disease starts from City Therapeutics and Surrozen and a pivotal Phase 2 trial of intravenous caffeine for faster recovery from anesthesia. China's InnoCare started a head-to-head Phase III trial in leukemia and a first-in-human bispecific ADC study. In Europe, Epitopea dosed the first patient with its off-the-shelf RNA ovarian cancer vaccine, while Australia had no new starts announced. At the end you'll find a summary of the trials that reached full enrollment. Each item links to the full release.
Nov 13, 2026
This week at a glance
We tracked seven first-patient-in milestones between 6 and 13 November. The US led with four, including two eye disease starts from City Therapeutics and Surrozen and a pivotal Phase 2 trial of intravenous caffeine for faster recovery from anesthesia. China’s InnoCare started a head-to-head Phase III trial in leukemia and a first-in-human bispecific ADC study. In Europe, Epitopea dosed the first patient with its off-the-shelf RNA ovarian cancer vaccine, while Australia had no new starts announced. At the end you’ll find a summary of the trials that reached full enrollment. Each item links to the full release.
United States
Eye disease led US starts this week. On 10 November, City Therapeutics dosed the first participant in a Phase 1 trial of CITY-RBP4, an RNA interference therapy for Stargardt disease type 1, an inherited cause of vision loss that usually begins in childhood. Initial Phase 1 data are expected in mid-2027. Read the full story. Surrozen also dosed its first patient in the Phase 1b portion of DUET, a Phase 1b/2a study of SZN-8141 in diabetic macular edema, and is expanding the Phase 2a part from about 60 to 150 patients (full release).
On 6 November, OYE Therapeutics dosed the first patient in a Phase 2 trial of OYE-101, an intravenous caffeine formulation designed to help adult surgical patients wake faster from general anesthesia and recover sooner. OYE intends the study to be the pivotal efficacy trial for a planned New Drug Application. Read the full story.
In oncology, Crescent Biopharma said in its third-quarter update on 13 November that it dosed the first patient earlier this month in APOLLO, a global Phase 1/2 trial of CR-002, a PD-L1-targeted antibody-drug conjugate with a topoisomerase inhibitor payload. Read the full release.
Asia
Beijing-based InnoCare Pharma had two starts in China this week. On 8 November it dosed the first patient in a head-to-head registrational Phase III trial comparing its BCL2 inhibitor mesutoclax plus azacitidine with venetoclax plus azacitidine, the current standard, in newly diagnosed acute myeloid leukemia. InnoCare reported earlier this year that 81.8% of evaluable treatment-naive AML patients achieved a composite complete remission with the mesutoclax combination. Read the full release.
Three days later, on 11 November, InnoCare dosed the first patient in a Phase I trial of ICP-B381, its first bispecific antibody-drug conjugate, which targets PSMA and STEAP1 in solid tumors. No bispecific ADC against these two targets has yet been approved. Read the full release.
We found no first-patient-in announcements from Japanese, Korean or other Asian sponsors between 6 and 13 November.
Australia
We found no new first-patient-in announcements from ASX-listed sponsors between 6 and 13 November. Australia did feature as a trial location: in its third-quarter update on 12 November, US-based Equillium gave more detail on its first-in-human Phase 1 trial of EQ504, which is running in Australia. The randomized, double-blind, placebo-controlled study will test single and multiple ascending doses in about 70 healthy participants. The first participant was dosed in late October, and proof-of-mechanism data are expected in Q2 2027. Read the full release.
Europe
On 9 November, Cambridge, UK and Montreal-based Epitopea dosed the first patient in OVACT, a first-in-human Phase 1/1b trial of CryptiVax-1001, an off-the-shelf RNA cancer vaccine for advanced high-grade serous ovarian cancer, the most common and aggressive form of the disease. Up to 30 women will be enrolled at as many as 10 UK centers, led by Professor Susana Banerjee of The Royal Marsden. The vaccine targets a set of tumor-specific antigens chosen to work across a broad range of patients rather than being made for each individual. Read the full release.
What to watch
DiaMedica will present preliminary results from its fetal growth restriction trial on 24 November. Crescent says the global APOLLO trial will enroll patients in the US, Europe and Asia-Pacific, so further site starts in those regions may follow. Many US biotechs are still reporting third-quarter results, which often confirm first-patient milestones that were not announced separately. Have a first-patient-in milestone to share? Reply to this newsletter and we will consider it for next week’s edition.
Fully recruited: enrollment completions, 6 to 13 November
Cardiology led this week’s completions. On 6 November, Kardigan completed enrollment of 156 patients in KATALYST-AV, its Phase 2b trial of ataciguat in mild-to-moderate aortic stenosis, with week-48 topline data expected in the second half of 2027. In its third-quarter update, Kardigan also confirmed that Cohort 2 of its Phase 2b KINSHIP-DCM trial of danicamtiv in dilated cardiomyopathy is fully enrolled, with topline data due in Q2 2027. Read the full story. DiaMedica said on 12 November that the first two of three dose cohorts are fully enrolled in an investigator-sponsored Phase 2 trial in early-onset fetal growth restriction, with preliminary results to be presented on 24 November (full story).
Just before the window, two US Phase 3 trials filled up. On 4 November, Intellia Therapeutics completed enrollment of about 60 patients in MAGNITUDE-2, testing a single infusion of its CRISPR gene-editing therapy nex-z in hereditary transthyretin amyloidosis with polyneuropathy (full release). On 3 November, Ardelyx completed enrollment ahead of schedule in ACCEL, a Phase 3 trial of IBSRELA (tenapanor) in chronic idiopathic constipation, with topline data expected in the second half of 2027 (full story). We found no enrollment completions from Asia-Pacific or European sponsors this week.
United States News
Asia News
Australia News
Europe News
What to watch
Fully recruited
Back to all issues